$2.62
1.87% yesterday
NYSE, Jun 02, 10:11 pm CET
ISIN
US44486Q1031
Symbol
HUMA
Sector
Industry

Humacyte Target price 2025 - Analyst rating & recommendation

Humacyte Classifications & Recommendation:

Buy
86%
Hold
14%

Humacyte Price Target

Target Price $9.43
Price $2.62
Potential
Number of Estimates 7
7 Analysts have issued a price target Humacyte 2026 . The average Humacyte target price is $9.43. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 6 Analysts recommend Humacyte to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Humacyte stock has an average upside potential 2026 of . Most analysts recommend the Humacyte stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates

7 Analysts have issued a sales forecast Humacyte 2025 . The average Humacyte sales estimate is

$7.7m
Unlock
. This is
1,384.71% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$10.4m 1,905.96%
Unlock
, the lowest is
$3.4m 548.15%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026
$73.0m 844.94%
Unlock
2027
$186m 154.75%
Unlock
2028
$377m 102.80%
Unlock
2029
$536m 42.25%
Unlock

6 Humacyte Analysts have issued a net profit forecast 2025. The average Humacyte net profit estimate is

$-31.0m
Unlock
. This is
45.43% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-24.5m 56.90%
Unlock
, the lowest is
$-43.4m 23.44%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026
$-40.0m 29.04%
Unlock
2027
$44.8m 212.19%
Unlock
2028
$214m 376.97%
Unlock
2029
$307m 43.67%
Unlock

Net Margin

2026
-54.77% 86.34%
Unlock
2027
24.12% 144.04%
Unlock
2028
56.72% 135.16%
Unlock
2029
57.29% 1.00%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
P/E negative
EV/Sales 46.77

6 Analysts have issued a Humacyte forecast for earnings per share. The average Humacyte EPS is

$-0.20
Unlock
. This is
53.49% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.16 62.79%
Unlock
, the lowest is
$-0.28 34.88%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026
$-0.26 30.00%
Unlock
2027
$0.29 211.54%
Unlock
2028
$1.38 375.86%
Unlock
2029
$1.98 43.48%
Unlock

P/E ratio

Current -6.09 20.99%
2025
-13.13 115.49%
Unlock
2026
-10.17 22.54%
Unlock
2027
9.07 189.18%
Unlock
2028
1.90 79.05%
Unlock
2029
1.32 30.53%
Unlock

Based on analysts' sales estimates for 2025, the Humacyte stock is valued at an EV/Sales of

46.77
Unlock
and an P/S ratio of
52.64
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 694.43
2025
46.77 93.26%
Unlock
2026
4.95 89.42%
Unlock
2027
1.94 60.75%
Unlock
2028
0.96 50.69%
Unlock
2029
0.67 29.70%
Unlock

P/S ratio

Current
2025
52.64 93.26%
Unlock
2026
5.57 89.42%
Unlock
2027
2.19 60.75%
Unlock
2028
1.08 50.69%
Unlock
2029
0.76 29.70%
Unlock

Current Humacyte Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Benchmark
Locked
Locked
Locked May 14 2025
D. Boral Capital
Locked
Locked
Locked May 13 2025
D. Boral Capital
Locked
Locked
Locked Mar 31 2025
D. Boral Capital
Locked
Locked
Locked Mar 28 2025
D. Boral Capital
Locked
Locked
Locked Mar 26 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 12 2025
D. Boral Capital
Locked
Locked
Locked Mar 07 2025
Analyst Rating Date
Locked
Benchmark:
Locked
Locked
May 14 2025
Locked
D. Boral Capital:
Locked
Locked
May 13 2025
Locked
D. Boral Capital:
Locked
Locked
Mar 31 2025
Locked
D. Boral Capital:
Locked
Locked
Mar 28 2025
Locked
D. Boral Capital:
Locked
Locked
Mar 26 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 12 2025
Locked
D. Boral Capital:
Locked
Locked
Mar 07 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today